Skip to main content
main-content

The independent medical news service

Chronic myeloid leukaemia

09-04-2018 | Leukaemia | News | Article

approvalsWatch

FDA announces further approvals for nilotinib, blinatumomab

Click through for more information about these leukemia decisions

07-03-2018 | Oncology | News | Article

News in brief

Dasatinib confirmed as pediatric chronic phase CML option

The tyrosine kinase inhibitor dasatinib is effective and well tolerated as a first- or second-line therapy for children with chronic myeloid leukemia in the chronic phase, research confirms.

05-01-2018 | Oncology | News | Article

approvalsWatch

Nilotinib update acknowledges discontinuation feasibility

Read more on this US FDA decision here

21-12-2017 | Oncology | News | Article

approvalsWatch

FDA approvals announced for advanced RCC, CML

Read more on these decisions here

29-08-2017 | Chronic myeloid leukaemia | News | Article

News in brief

First-line imatinib at 10 years: CML patients achieve ‘close to normal life expectancy’

Findings from the chronic myeloid leukemia IV study suggest that patients in the chronic phase who respond to imatinib have a high likelihood of survival at 10 years.

22-06-2017 | Chronic myeloid leukaemia | Main feed | News

ASCO 2017

Frontline bosutinib ‘an option’ for newly diagnosed CP CML

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

Source:

J Clin Oncol 2017; 35: 7002

19-04-2017 | Chronic myeloid leukaemia | News | Article

First-line generic imatinib offers ‘suboptimal efficacy’

For patients undergoing front-line treatment for chronic myeloid leukemia, generic treatment may be less effective than the branded agent, researchers suggest, but treatment efficacy is maintained in patients who switch from a branded to a generic formulation.

Source:

Clin Lymphoma Myeloma Leuk 2017; Advance online publication

12-04-2017 | Chronic myeloid leukaemia | News | Article

Molecular response depth may predict imatinib resistance risk

Study findings suggest that the depth of molecular response to imatinib achieved by a patient with chronic myeloid leukemia may influence the relationship between a fluctuating response to treatment and the likelihood of developing resistance to the tyrosine kinase inhibitor.

Source:

Br J Haematol 2017; Advance online publication

29-03-2017 | Chronic myeloid leukaemia | News | Article

CML treatment-free remission possible with nilotinib

The ENESTfreedom study of patients who stopped first-line nilotinib after achieving a sustained deep molecular response has shown that around half of chronic myeloid leukemia patients continue in remission.

Source:

Leukemia 2017; Advance online publication

29-03-2017 | Chronic myeloid leukaemia | News | Article

CML progression, outcome linked to smoking

Findings from the German CML Study IV indicate that patients with chronic myeloid leukemia are more likely to experience disease progression and have lower overall survival if they smoke.

Source:

Cancer 2017; Advance online publication                  

17-03-2017 | Chronic myeloid leukaemia | News | Article

Imatinib efficacy for CML sustained over time

Overall survival among patients with chronic myeloid leukemia remains high after nearly 11 years of treatment with imatinib, analysis of phase III study data shows.

Source:

N Engl J Med 2017; 376: 917–927, 982–983

06-01-2017 | Chronic myeloid leukaemia | News | Article

CD62L T-cell expression linked to TKI therapy response

Chronic myeloid leukemia patients with high CD62L T-cell expression and low soluble CD62L plasma levels at diagnosis have the best chance of achieving a deep molecular response to first-line therapy with tyrosine kinase inhibitors, study findings indicate.

Source:

J Clin Oncol 2016; Advance online publication

04-01-2017 | Chronic myeloid leukaemia | News | Article

Editor's pick

Imatinib kinetic response similar in children and adults

Primary kinetic responses to the tyrosine kinase inhibitor imatinib do not differ significantly between children and adults with chronic myeloid leukemia, German study data show.

Source:

Haematologica 2016; Advance online publication

30-12-2016 | Chronic myeloid leukaemia | News | Article

Mature NK cells play key role in continued CML remission

Patients with chronic myeloid leukemia who successfully discontinue imatinib treatment have a higher proportion of mature natural killer cells than those who experience early relapse, a substudy of the EURO-SKI data shows.

Source:

Leukemia 2016; Advance online publication

28-12-2016 | Chronic myeloid leukaemia | News | Article

Fecal occult blood test ‘useful’ for detecting dasatinib-induced hemorrhagic colitis

Japanese researchers say that a fecal occult blood test could help screen for treatment-induced hemorrhagic colitis in chronic myeloid leukemia patients taking dasatinib.

Source:

Blood 2016; Advance online publication

01-12-2016 | Chronic myeloid leukaemia | News | Article

STIM1 findings confirm safety of controlled imatinib discontinuation

Final results of the Stop Imatinib trial confirm that the tyrosine kinase inhibitor can be safely discontinued in chronic myeloid leukemia patients who achieve a sustained deep molecular response.

Source:

J Clin Oncol 2016; Advance online publication 

28-11-2016 | Chronic myeloid leukaemia | News | Article

CML somatic mutation analysis linked to patient outcome

Researchers have identified six different patterns of somatic mutation acquisition, persistence, and clearance in patients with chronic myeloid leukemia, with a significant link between these and tyrosine kinase inhibitor therapy response.

Source:

Blood 2016; Advance online publication

28-11-2016 | Chronic myeloid leukaemia | News | Article

Editor's pick

Pleural effusion linked to first-line dasatinib molecular response

Pleural effusion may be a positive sign during dasatinib treatment in patients with chronic phase chronic myeloid leukemia, suggests research published in Oncology Reports.

Source:

Oncol Rep 2016; Advance online publication

04-11-2016 | Chronic myeloid leukaemia | News | Article

‘Major role’ for first-line dasatinib in elderly CML patients

First-line treatment with dasatinib is effective and well tolerated in chronic myeloid leukaemia patients aged over 65 years, shows an Italian clinical practice study.

Source:

Neoplasia 2016; 18: 536–540

04-11-2016 | Chronic myeloid leukaemia | News | Article

EUTOS data give real-world overview of TKI use

European Treatment and Outcome Study findings suggest that real-world use of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia reflects that seen in clinical trials.

Source:

Leukemia 2016; Advance online publication

image credits